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ABSTRACT 
Background: 
Preoperative neutrophil to lymphocyte ratio (NLR) might be prognostic in papillary thyroid 
carcinoma (PTC). Given the controversy of prophylactic central neck dissection (pCND) in 
clinically-nodal negative (cN0) PTC, our study evaluated whether preoperative NLR predicted 
disease-free survival (DFS) and occult central nodal metastasis (CNM) in cN0 PTC. 
Methods: 
One hundred and ninety-one patients who underwent pCND were analyzed. Complete blood 
counts with differential counts were taken before operation. NLR was calculated by dividing 
preoperative neutrophil count with lymphocyte count. Patients were categorized into NLR 
tertiles, namely the first (NLR<1.93) (n=63), second (NLR=1.93–2.79) (n=64) and third tertile 
(NLR>2.79) (n=64). Four other patient types namely, benign nodular goiter, clinically-nodal 
positive (cN1) PTC, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma 
(ATC) were used as references. 
Results: 
Age at operation (p<0.001) and tumor size (p=0.037) significantly increased with higher NLR. 
First tertile had significantly more TNM Stage I tumors (p=0.010) and lowest MACIS score 
(p=0.002). Tumor size (HR=1.422,95%CI=1.119 – 1.809,p=0.004) and multicentricity 
(HR=2.545,95%CI=1.073 – 6.024,p=0.034) independently predicted DFS while old age 
(OR=1.026,95%CI=1.006 – 1.046, p=0.009), male (OR=2.882,95%CI=1.348 – 6.172,p=0.006) 
and large tumor (OR=1.567,95%CI=1.209 – 2.032,p=0.001) independently predicted occult 
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CNM. NLR was not significantly associated with DFS or occult CNM. ATC had significantly 
higher NLR than cN1 PTC (7.28 vs. 2.74,p<0.001). 
Conclusions: 
Although a higher NLR may imply a poorer tumor profile, it was not significantly associated 
with a worse DFS or higher risk of occult CNM in cN0 PTC. Perhaps, future research should 
focus on the prognostic value in other thyroid cancer types with a poorer prognosis. 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid 
carcinoma and its age-adjusted incidence has doubled in the last 25 years.1 Despite its relatively 
good prognosis with a 10-year cancer-specific survival above 90%, locoregional recurrence 
(LRR) is common.2 With recognition of the concept of step-wise progression of lymph node 
metastasis originating from the central (level VI) to the lateral compartment (levels II-V) and the 
fact that preoperative ultrasonography (USG) could only identify approximately half of the 
central nodal metastasis (CNM), a growing number of surgeons are advocating routine 
prophylactic central neck dissection (pCND) at the time of the total thyroidectomy (TT).3-5 But 
since this appears to be at the expense of having higher surgical morbidities,6 a more selective 
approach based on risk factors for CNM has been advocated.7 
It has been recognized that systemic inflammation commonly occurs in the presence of 
many human cancers including thyroid carcinoma and the neutrophil to lymphocyte ratio (NLR) 
is one of the most reliable biomarkers for measuring the level of systemic inflammation.8-10 NLR 
has been shown to be a convenient and inexpensive prognostic biomarker in many human 
cancers.8-11 Potential mechanisms underlying the prognostic significance of NLR may be an 
association with lower immuno-competence, and/or lowering of the neutrophil count from a 
stimulating tumor microenvironment8-11. To our knowledge, only two studies have examined its 
significance in PTC.12-13 Seretis et al. compared the NLR between those with an incidental 
papillary microcarcinoma and those with a benign goiter only and found that the former group 
had a significantly higher mean NLR than the latter group (3.0 vs. 1.9, p<0.001). The authors 
concluded that NLR could potentially be used as a biomarker for detecting incidental small PTC 
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in an apparently benign goiter.12 Liu et al. studied the correlation between preoperative NLR and 
tumor characteristics and risk and found that a higher preoperative NLR was significantly 
associated with a larger-sized tumor and a greater risk of recurrence based on the American 
Thyroid Association (ATA) staging system.13,14 As a result, NLR might be a promising serum 
biomarker for diagnosis and prognostication of PTC.  
In view of these findings and the fact that one of the main controversies in PTC is 
deciding on whether to perform pCND or not at the time of TT in clinically-nodal negative (cN0) 
PTC, our study was aimed to evaluate the utility of preoperative NLR in determining disease-
free survival (DFS) and in predicting occult CNM in cN0 PTC.
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PATIENTS AND METHODS 
Patients 
From January 2004 – October 2012, 229 consecutive patients with cN0 PTC underwent a 
routine unilateral pCND at the time of TT and were retrospectively analyzed. All patients had no 
evidence of CNM on preoperative USG or at operation. To avoid possible confounders for NLR, 
patients with a condition known to affect the total and differential white cell count (WCC) such 
as hematologic disorder (n=9), other malignancy or cancer treatment within the last 12 months 
(n=20), acute myocardial infarction / coronary revascularization within 6 months (n=1), active 
infection or glucocorticoids use within 3 months (n=2), preoperative thyroid-stimulating 
hormone (TSH) outside normal range (i.e. <0.35 or >4.78mIU/L) (n=6) were excluded. After 
excluding these patients, 191 (83.4%) cN0 PTC patients were eligible for analysis. All patients 
had complete blood counts with automated differential counts taken one day before elective 
thyroidectomy. NLR was calculated by dividing the absolute neutrophil count with the absolute 
lymphocyte count. To evaluate the association between NLR and other tumor clinicopathologic 
features and outcomes, patients were categorized into 3 tertiles, namely the first tertile or group I 
(NLR<1.93) (n=63), the second tertile or group II (NLR=1.93 – 2.79) (n=64) and the third tertile 
or group III (NLR>2.79) (n=64). 
To further appreciate the association between NLR and clinicopathologic features in 
other thyroid diseases, four other patient groups were analyzed. They comprised 192 patients 
with benign nodular goiter, 48 patients with clinically nodal (cN1) PTC, 20 patients with poorly 
differentiated thyroid carcinoma (PDTC) and 15 patients with anaplastic thyroid carcinoma 
(ATC) during the study period. They were selected based on the same exclusion criteria as above. 
Patients with follicular/hurthle cell adenoma or occult PTC were excluded. The WCC, neutrophil 
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and lymphocyte counts and NLR were compared between the benign goiter, cN0 PTC, cN1 PTC, 
PDTC and ATC groups.  
Methods 
All cell counts were done in our own institution’s laboratory. All relevant clinical, 
laboratory, radiologic, and perioperative data were collected prospectively and follow-up data 
were regularly updated in a computerized database. The present study protocol was approved by 
the local institutional review board. Patient clinicopathological features and postoperative 
outcomes were compared between the three tertiles. 
Management of PTC 
Details of surgical treatment and follow-up protocol had been described previously.15,16 A 
routine ipsilateral pCND was performed for all regardless of tumor size or extent.15 The pCND 
consisted of the removal of all nodes and fibro-fatty tissue extending vertically from the hyoid 
bone to the thoracic inlet and laterally from the medial border of common carotid artery to the 
midline of the trachea. The ipsilateral recurrent laryngeal nerve was mobilized and skeletonized 
along its entire cervical course. An intraoperative nerve stimulator was used to confirm its 
functional integrity.17 Parathyroid autotransplantation was readily performed. Stimulated 
thyroglobulin (sTg) was defined as a Tg level measured in the presence of TSH >30 mIU/L 
either by thyroxine withdrawal or recombinant TSH injections. The pre-ablation sTg level was 
taken approximately 2 months after surgery while the post-ablation level was taken 
approximately 9 months after surgery (6-7 months after RAI ablation). Tg autoantibodies were 
measured at the same time. The decision for RAI ablation was based on presence of ≥1 risk 
factors such as tumor size > 1.5cm, lymph node metastasis, age >45 years old, extrathyroidal 
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extension, macroscopic postoperative residual disease in the neck and distant metastasis. Three 
giga-Becquerels (GBq) or 80millicuries (mCi) I131 was the standard fixed ablative dose.  
Follow-up protocol 
All post-surgical patients were followed up within 4 weeks in a specialized combined 
oncology clinic. A follow-up visit was conducted at 3-month intervals in the first 2 years, 6-
month in the subsequent 3 years and annually thereafter. Clinical examination, neck USG and 
non-stimulated Tg level were done during follow-up visits. LRRs were frequently diagnosed by 
USG, CT/ MRI or FDG-PET scan and confirmed by fine needle aspiration cytology. 
Statistical analysis 
Statistical analysis was performed by chi-square or Fisher’s Exact test to compare 
categorical variables, and Mann-Whitney U or Kruskal-Wallis test was used to compare 
continuous variables between groups. For correlation between two continuous variables, the 
Pearson correlation test was performed. Continuous variables were expressed as mean±SD. 
Disease-free survival (DFS) was estimated using the Kaplan-Meier method and compared by the 
log-rank test. Linear regression was used to model the correlation between NLR and two or more 
continuous significant variables. Variables which were significant in the univariate analysis were 
entered into multivariate analysis. Cox regression or binary logistic regression analysis with a 
variable entrance criterion of 0.05 or less was conducted to identify independent factors. All 
statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).
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RESULTS 
Our cohort was mostly females (79.1%) and ethnic Chinese (94.2%). The mean age at 
operation was 47.9 ± 15.8 years old. The mean (±SD) tumor size was 1.87 ± 1.36cm. The mean 
(±SD) total number of central lymph nodes (CLNs) and positives CLNs removed were 5.7 ± 1.0 
and 2.6 ± 1.0, respectively. The mean (±SD) and median (range) NLR in our cohort were 
2.68±1.84 and 2.29 (0.52 – 16.6), respectively.  After a mean follow-up was 41.3 ± 26.5 months, 
all patients were still alive. There were 12 patients with recurrence and of these, 11 were 
confined locoregionally while 1 had locoregional and distant recurrences. The mean duration to 
first recurrence was 20.4 ± 15.3 months. The 5-year recurrence rate was 9.1%. 
Table 1 shows a comparison of clinicopathological features, blood parameters, TNM 
tumor stages and MACIS score between the 3 tertiles.  The mean age was significantly different 
(p<0.001) with the third tertile having the oldest age. There was a significant direct correlation 
between age and NLR (ρ= 0.281, p<0.001). Total WCC (p=0.002) and neutrophil count (p<0.001) 
were significantly higher with higher tertiles while lymphocyte count (p<0.001) was significantly 
lower with higher tertiles. Tumor size was also significantly increased with higher tertiles 
(p=0.037). However, there was no significant correlation between age and tumor size (ρ= -0.008, 
p=0.896). Tumor characteristics including tumor bilaterality, multifocality, capsular invasion, 
extrathyroidal extension, coexisting thyroiditis, presence of CNM, number of CLNs and positive 
CLNs were similar between the tertiles. Regarding TNM staging, the first tertile had more Stage I 
tumors than the second and third tertiles (71.4% vs. 53.1 and 48.4%, p=0.010). Although not 
significant, the first tertile tended to have less Stage III and IV tumors than the second and third 
tertiles (15.9% vs. 28.1% and 31.3% and 9.4% vs. 15.6% and 17.2%, respectively). The first 
tertile also had the lowest MACIS score when compared to the second and third tertiles (4.68 vs. 
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5.04 and 5.60, p=0.002). However, after adjusting for age in a regression analysis, neither TNM 
stages (p=0.335) nor MACIS (p=0.976) remained significantly correlated with NLR.  
Figure 1 shows the cumulative DFS curves between the three tertiles. 
Table 2 shows the Cox regression analysis for DFS. In the univariate analysis, tumor size 
(HR=1.403,95%CI=1.097 – 1.796,p=0.007), extrathyroidal extension (HR=2.290, 
95%CI=1.026 – 5.113, p=0.043), multicentricity (HR=2.734,95%CI=1.170 – 6.390, p=0.020), 
lymphovascular permeation (HR=2.875,95%CI=1.287 – 6.426, p=0.010) and occult CNM 
(HR=3.083, 95%CI=1.302 – 7.978, p=0.002) were associated with a worse DFS. NLR did not 
significantly determine DFS. In the multivariate analysis, tumor size (HR=1.422; 
95%CI=1.119 – 1.809, p=0.004) and multicentricity (HR=2.545,95%CI=1.073 – 6.024, p=0.034) 
independently predicted worse DFS. 
Table 3a shows a comparison of patient clinicopathologic features and blood parameters 
between those with occult CNM (N1a group) and those without occult metastases (N0 group). 
The N1a group was significantly younger (45.2 years vs. 51.0 years, p=0.001), more male 
(28.2% vs. 15.9%, p=0.023), had larger tumor (2.42cm vs. 1.45cm, p=0.001) and more 
lymphovascular permeation (35.9% vs. 15.9%, p=0.004). Tumor multicentricity almost reached 
significance (p=0.083). Other blood parameters including NLR were not significant. Table 3b 
shows the multivariate analysis for occult CNM. Younger age (OR=1.026, 95%CI=1.006 – 1.046, 
p=0.009), male sex (OR=2.882, 95%CI=1.348 – 6.172, p=0.006) and larger tumor size 
(OR=1.567, 95%CI=1.209 – 2.032, p=0.001) were independent predictors of occult CNM. 
NLR in benign nodular goiter, cN1 PTC, PDTC and ATC 
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Unlike cN0 PTC, age was not significantly associated with NLR (p=0.883) in benign 
nodular goiter. There were also no significant associations between NLR and clinicopathologic 
features in the benign nodular goiter, cN1 PTC, PDTC and ATC groups. 
Table 4 compares age and blood parameters between benign nodular goiter, cN0 PTC, 
cN1 PTC, PDTC and ATC.  There were no significant differences in NLR between benign goiter 
and cN0 PTC (p=0.492), between cN0 PTC and cN1 PTC (p=0.951) and between PDTC and 
ATC (p=0.299) but there was a significant difference between cN1 PTC and ATC (p<0.001). 
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DISCUSSION 
Although using NLR as a biomarker for predicting prognosis has been well demonstrated 
in many non-thyroidal cancers, the evidence supporting its role as a prognostic biomarker in PTC 
remains relatively scarce.8-10,12,13 Nevertheless, using NLR as a biomarker is attractive because it 
is relatively cheap and more importantly, readily available. To our knowledge, two studies have 
examined the significance of NLR in PTC and one of them has found that the group with the 
higher NLR had significantly larger sized tumors and greater ATA risk for recurrence.12,13  
Similar to this previous study, our data found a higher NLR implied a poorer tumor risk 
profile. The third tertile had significantly older patients (54.1 vs. 42.0 years, p<0.001) and larger 
sized tumors (1.92cm vs. 1.72cm, p=0.037) than first tertile and both age and tumor size 
appeared independent as there was no significant correlation between the two (p=0.896). 
Interestingly though, a similar relationship between NLR and age was not observed in benign 
nodular goiter and ATC and so this direct correlation between age and NLR might only be 
present in PTC only. Consistent to these findings, our data also found that the the first NLR 
tertile had significantly more TNM stage I tumors (71.4% vs. 48.4%, p=0.010) and lower MACIS 
score (4.68 vs. 5.60, p=0.002) than the third tertile. However, it should be noted that when age 
had been adjusted for in the regression analysis, neither TNM nor MACIS remained significantly 
correlated with NLR. The exact explanation for the poorer tumor risk profile remains unclear but 
since a higher NLR was a result of increased neutrophil count relative to lymphocyte count, one 
possible explanation would be that activated neutrophils might directly or indirectly stimulate 
tumor growth as suggested in previous studies.18 Although the relationship between NLR and 
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age was not reported in the two previous studies on PTC and in our small cohort of ATC,12,13 this 
was observed in other non-thyroidal cancers.9-10 
Given the controversy of pCND and the significant correlation between NLR and age, 
tumor size, TNM stage I and MACIS score, it was further analyzed to determine whether it was 
associated with DFS and occult CNM in cN0 PTC. In the univariate analysis for DFS, even 
though the hazard ratio was greater than one, NLR did not reach significance (HR=1.127, 
95%CI=0.932 – 1.363, p=0.224). In the multivariate analysis, after adjusting for extrathyroidal 
extension, lymphovascular permeation and N1a, larger tumor size (HR=1.422, 95%CI=1.119 – 
1.809, p=0.004) and multicentricity (HR=2.545, 95%CI=1.073 – 6.024, p=0.034) turned out to 
be independent predictors for worse DFS. This was consistent to our previous analysis which 
found that tumor size was a risk factor for having detectable post-ablative stimulated Tg (a 
surrogate for persistent / recurrent disease) in cN0 PTC.19 A recent study has also reported 
similar findings with tumor size (OR=1.93) and extrathyroidal extension (OR=12.47) as risk 
factors for LRR in cN0 PTC.19 Interestingly, this study also found adding pCND reduced LRR 
(OR=0.21, 95%CI=0.11 – 0.41, p<0.001).20 
In the univariate analysis for occult CNM, although the mean NLR appeared greater in 
the N1a group than N0 group, it was not significantly different (2.70 vs 1.41, p=0.275) and so 
NLR was not entered into the multivariate analysis. Consistent with other previous studies, our 
data showed that younger age (OR=1.026, 95%CI=1.006 – 1.046, p=0.009), male sex 
(OR=2.882, 95%CI=1.348 – 6.172, p=0.006) and larger tumor size (OR=1.567, 95%CI=1.209 – 
2.032, p=0.001) were independent predictors for occult CNM in cN0 PTC.7,21-26 However, unlike 
previous studies,21,22,26 lymphovascular permeation turned out to be significant only in the 
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univariate and not in the multivariate analysis (OD=1.946, 95%CI=0.919 – 4.122, p=0.082). 
Other significant predictors for occult CNM included extrathyroidal extension and 
multicentricity but they were not found to be significant in the present analysis.7,21-23,25-27 
Although the presence of BRAF mutation in the primary tumor has been found to be a possible 
predictor for occult CNM, this has not been consistently shown and was not assessed here.26,28  
Therefore, although a higher NLR may imply a poorer tumor profile, it was not 
significantly enough to predict a worse DFS or higher risk of occult CNM in cN0 PTC. One 
possible reason might be because the prognosis of cN0 PTC is generally very good and so its 
NLR is expected to be within the low and narrow range (mean±SD was 2.70±1.91). In fact, NLR 
were not significantly different between benign nodular goiter and cN0 PTC, between cN0 PTC 
and cN1 PTC and between PDTC and ATC (see Table 4). There was only a significant 
difference in NLR between cN0 PTC and ATC (p<0.001). These data implied that NLR might be 
an indicator for histological differentiation and prognosis but not a strong enough indicator for 
differentiating between cN0 and cN1 PTC or between PDTC and ATC. 
However, despite these findings, our data should be interpreted cautiously as this was a 
relatively moderate-sized study and that tended to limit the power of the study to identify smaller 
effects. Also since this study was retrospective, it was prone to selection biases.    
Conclusion 
Although a higher preoperative NLR was significantly associated with older age at operation, 
larger primary tumor size, more advanced TNM stages and higher MACIS score, it did not predict 
a worse DFS or risk of occult CNM in patients with cN0 PTC. Perhaps, a larger-scale 
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prospective study should be conducted to further evaluate the prognostic significance of 
preoperative NLR in other thyroid cancer types with a significantly worse prognosis than PTC. 
Clinicopathologic factors remained more significant predictors of DFS and occult CNM.
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Table 1. A comparison of patient clinicopathological features, blood parameters, TNM tumor 
stages and MACIS score between those with a neutrophil lymphocyte ratio (NLR) < 1.93 (First 
tertile), NLR = 1.93 – 2.79 (Second tertile) and NLR > 2.79 (Third tertile). 
 First tertile 
(NLR<1.93) 
(n=63) 
Second tertile 
(NLR=1.93 – 
2.79) (n=64) 
Third tertile 
(NLR>2.79) 
(n=64) 
p-value 
Age at operation (years) 42.03 ± 16.04 50.42 ± 13.47 54.13 ± 15.06 <0.001 
Sex 
- Male 
- Female 
 
9 (14.3) 
54 (85.7) 
 
14 (21.9) 
50 (78.1) 
 
17 (26.6) 
47 (73.4) 
0.230 
Presented as a palpable neck 
swelling 
17 (27.0) 25 (39.1) 26 (40.6) 0.214 
Serum TSH (mIU/L) 1.55 ± 1.10 1.40 ± 0.99 1.34 ± 0.99 0.685 
Hemoglobin (g/dL) 12.82 ± 1.36 13.02 ± 1.45 12.68 ± 1.65 0.390 
Platelet count (109/L) 258.62 ± 68.51 253.69 ± 64.27 241.98 ± 75.78 0.274 
Total white cell count (109/L) 5.64 ± 1.49 6.36 ± 1.52 6.72 ± 1.94 0.002 
Neutrophil count (109/L) 2.95 ± 0.91 4.00 ± 1.01 4.92 ± 1.60 <0.001 
Lymphocyte count (109/L) 2.13 ± 0.66 1.76 ± 0.43 1.24 ± 0.39 <0.001 
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Neutrophil lymphocyte ratio 1.41 ± 0.35 2.28 ± 0.25 4.39 ± 1.9 <0.001 
Tumor characteristics 
- Tumor size (cm) 
- Tumor bilaterality 
- Multifocality 
- Extra-thyroidal extension 
- LV permeation 
- Coexisting thyroiditis 
- Occult CNM (pN1a) 
 
1.46 ± 1.47 
17 (27.0) 
25 (39.7) 
19 (30.2) 
10 (15.9) 
13 (20.6) 
23 (36.5) 
 
1.81 ± 1.10 
18 (28.1) 
24 (37.5) 
23 (35.9) 
15 (23.4) 
10 (15.6) 
27 (42.2) 
 
2.13 ± 1.31 
15 (23.4) 
23 (35.9) 
18 (28.1) 
11 (17.2) 
14 (21.9) 
28 (43.8) 
 
0.037 
0.820 
0.644 
0.566 
0.309 
0.639 
0.215 
Follicular-variant of PTC 7 (11.1) 5 (7.8) 9 (14.1) 0.377 
Number of central lymph 
nodes retrieved 
5.5 ± 1.0 5.7 ± 1.0 6.3 ± 1.0 0.969 
Number of metastatic central 
lymph nodes excised 
2.6 ± 1.0 2.6 ± 1.0 2.6 ± 1.0 0.192 
Stage of PTC by TNM 
- Stage I 
- Stage II 
 
45 (71.4) 
2 (3.2) 
 
34 (53.1) 
2 (3.1) 
 
31 (48.4) 
2 (3.1) 
 
0.010 
1.000 
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- Stage III 
- Stage IV 
10 (15.9) 
6 (9.4) 
18 (28.1) 
10 (15.6) 
20 (31.3) 
11 (17.2) 
0.098 
0.210 
Radioiodine ablation 47 (74.6) 48 (75.0) 49 (76.6) 0.952 
Pre-ablation sTg level 
(mIU/L) 
1.5 ± 0.9 1.2 ± 0.9 2.2 ± 0.9 0.222 
Post-ablation sTg level 
(mIU/L) 
0.2 ± 0.1 0.4 ± 0.2 0.5 ± 0.2 0.456 
MACIS score 4.68 ± 1.39 5.04 ± 1.10 5.60 ± 1.20 0.002 
Continuous variables are expressed as median (range); categorical variables are expressed as 
number (percentage) 
Abbreviations: PTC = papillary thyroid carcinoma; LV= lymphovascular; CNM = central nodal 
metastasis; TNM = 7th edition Tumor, Node and Metastasis staging system; MACIS = Metastases, 
Age, Completeness of surgery, Invasion and Size; sTg = stimulated thyroglobulin
25 
 
Table 2. Cox regression analysis of disease-free survival in 191 clinically-nodal negative (cN0) papillary thyroid carcinoma 
 Univariate analysis Multivariate analysis 
Variable Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value 
Age 0.984 0.959 – 1.010 0.229    
Female sex 0.536 0.229 – 1.254 0.150    
TSH 0.656 0.355 – 1.212 0.178    
Tumor size 1.403 1.097 – 1.796 0.007 1.422 1.119 – 1.809 0.004 
ETE 2.290 1.026 – 5.113 0.043 0.604 0.268 – 1.363 0.225 
Multicentricity 2.734 1.170 – 6.390 0.020 2.545 1.073 – 6.024 0.034 
LV permeation 2.875 1.287 – 6.426 0.010 1.869 0.811 – 1.869 0.142 
N1a 3.016 1.122 – 8.106 0.029 2.227 0.816 – 6.098 0.118 
Tumor bilaterality 1.034 0.410 – 2.605 0.944    
White cell count 1.190 0.940 – 1.505 0.148    
NLR 1.127 0.932 – 1.363 0.219    
Neutrophil count 1.192 0.906 – 1.570 0.210    
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Lymphocyte count 1.336 0.601 – 2.970 0.477    
RAI ablation 1.492 0.343 – 6.492 0.594    
Abbreviations: TSH = thyroid stimulating hormone; ETE = extrathyroidal extension; LV = lymphovascular; N1a = occult central 
lymph node metastases; NLR = neutrophil to lymphocyte ratio; CI = confidence interval; RAI = radioiodine  
Bold letters signify statistical significance (p<0.05)
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Table 3a. A comparison of patient clinicopathologic features and blood parameters between 
those with occult central nodal metastases (N1a) and those without occult central nodal 
metastases (N0) 
 N1a group (n=78) N0 group (n=113) p-value 
Age at operation (years) 45.21 ± 17.15 51.04 ± 13.32 0.001 
Sex (Male : Female) 22 : 56 18 : 95 0.023 
Serum TSH (mIU/L) 1.55 ± 1.03 1.41 ± 0.96 0.965 
Hemoglobin (g/dL) 12.85 ± 1.58 12.85 ± 1.39 0.175 
Platelet count (109/L) 247.96 ± 68.62 254.15 ± 70.51 0.712 
Total white cell count (109/L) 6.17 ± 1.81 6.35 ± 1.62 0.233 
Neutrophil count (109/L) 3.85 ± 1.56 4.10 ± 1.31 0.183 
Lymphocyte count (109/L) 1.74 ± 0.69 1.68 ± 0.54 0.781 
Neutrophil lymphocyte ratio 2.70 ± 1.42 1.41 ± 0.96 0.275 
Tumor characteristics 
- Tumor size (cm) 
- Tumor bilaterality 
- Multifocality 
 
2.42 ± 1.45 
22 (28.2) 
27 (34.6) 
 
1.45 ± 1.11 
28 (24.8) 
45 (39.8) 
 
0.001 
0.627 
0.352 
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- Extra-thyroidal extension 
- LV permeation 
30 (38.5) 
28 (35.9) 
30 (26.5) 
18 (15.9) 
0.083 
0.004 
 
Table 3b. A multivariable analysis of clinicopathological risk factors for occult central lymph 
node metastases (N1a)  
Covariates ß-coefficient Odds ratio (95% confidence 
interval) 
p-value 
Age at operation -0.026 1.026 (1.006 – 1.046) 0.009 
Male sex 1.065 2.882 (1.348 - 6.172) 0.006 
Tumor size 0.444 1.567 (1.209 – 2.032) 0.001 
LV permeation 1.058 1.946 (0.919 – 4.122) 0.082 
Abbreviations: TSH = thyroid stimulating hormone; LV = lymphovascular 
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Table 4 shows a comparison of age and blood parameters between benign nodular goiter, clinically-nodal negative (cN0) and positive 
(cN1) papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) 
 Benign goiter 
(n=192) 
cN0 PTC 
(n=191) 
cN1 PTC 
(n=58) 
PDTC 
(n=13) 
ATC 
(n=15) 
p-
value* 
p-
value+ 
p-
value# 
p-
value^ 
Age at operation 
(yrs) 
49.52 ± 14.17 47.90 ± 15.80 50.47 ± 8.7 72.0 ± 18.47 76.73 ± 8.75 0.589 0.441 <0.001 0.818 
Total white cell 
count (109/L) 
6.33 ± 1.83 6.38 ± 1.90 6.39 ± 1.95 6.43 ± 4.16 10.34 ± 4.23 0.930 0.866 <0.001 0.004 
Neutrophil count 
(109/L) 
4.10 ± 1.64 4.02 ± 1.51 3.87 ± 1.18 4.73 ± 4.21 8.06 ± 4.23 0.868 0.674 <0.001 0.006 
Lymphocyte 
count (109/L) 
1.66 ± 0.55 1.73 ± 0.61 1.74 ± 0.76 1.07 ± 0.52 1.36 ± 0.61 0.336 0.532 0.123 0.181 
Neutrophil 
lymphocyte ratio 
2.80 ± 1.77 2.68 ± 1.84 2.74 ± 2.32 6.36 ± 6.68 7.28 ± 4.64 0.492 0.951 <0.001 0.299 
*between benign nodular goiter and cN0 PTC 
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+between cN0 PTC and cN1 PTC 
#between cN1 PTC and ATC 
^between PDTC and ATC 
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LEGENDS 
Figure 1. The cumulative disease-free survival curves of clinically nodal negative papillary thyroid carcinoma with a preoperative 
neutrophil to lymphocyte ratio (NLR) < 1.93 (n=63, first tertile), NLR = 1.93 – 2.79 (n=64, second tertile) and NLR > 2.79 (n=64, 
third tertile) 
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